KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Jazz’s move into the KRAS category comes shortly after AstraZeneca licensed a KRAS G12D inhibitor from Chinese biotech Usynova for $24 million upfront in a deal that also includes up to $395 ...

常见的 KRAS 突变类型有 G12C、G12D、G12R、G12A 等。 全球现有 4 款 KRAS 抑制剂获批上市，但都是 KRAS G12C 抑制剂，仍存在较大的尚未满足的临床需求。

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor.

Lac inhibits Tregs activity and promotes antitumor immunity in a mouse primary lung cancer model. In addition, Lac synergizes with PD-1 inhibitor to shrink lung cancers driven by mutant KRAS in a ...

At close: 12 February at 4:00:00 pm GMT-5 ...